EGFR and neoplasm: In advanced tumor stages, IIIB–IV, we found EGFR mutations in 12.0% (78/650) of ACAs, in 1.1% of SCCs (1/87; p.Glu865Lys), and in 6.7% of ASCs (1/15; p.Ser768_Asp770dupSerValAsp).